Clinical Trials Logo
  1. Home
  2. Proliferative Vitreoretinopathy
  3. NCT00373282
  4. Details
NCT00373282 Clinical Trial

Triamcinolone Acetonide in Silicone-Filled Eyes as Adjunctive Treatment for Proliferative Vitreoretinopathy

Proliferative Vitreoretinopathy Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00373282
Other study ID # 8116
Secondary ID
Status Completed
Phase Phase 3
First received September 7, 2006
Last updated October 11, 2006
Start date June 2001
Est. completion date June 2003

Study information
Verified date August 2006
Source hahid Beheshti University of Medical Sciences
Contact n/a
Is FDA regulated No
Health authority Iran: Ethics Committee
Study type Interventional

Clinical Trial Summary

To evaluate the effect of triamcinolone acetonide in silicone-filled eyes on the outcome of surgery for PVR.

Recruitment information / eligibility
Status Completed
Enrollment 0
Est. completion date June 2003
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Cases of rhegmatogenous retinal detachment complicated by PVR grade C undergoing vitrectomy and silicone oil tamponade.

Exclusion Criteria:

- History of trauma

- Presence of diabetic retinopathy

- History of vein occlusion

- Giant retinal tear

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind, Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Triamcinolone acetonide

Locations
Country Name City State
Iran, Islamic Republic of Hamid Ahmadieh,MD Tehran

Sponsors (1)
Lead Sponsor Collaborator
hahid Beheshti University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

Outcome
Type Measure Description Time frame Safety issue
Primary Single-operation retinal reattachment rate six
Primary months after surgery.
Secondary Visual acuity
Secondary Retinal reproliferation
Secondary Intraocular pressure
Secondary Early silicone oil emulsification
See also
  Status Clinical Trial Phase
Recruiting NCT05561569 - Air Versus Gas Tamponade in Primary Retinal Detachment N/A
Not yet recruiting NCT05538156 - Internal Limiting Membrane Peeling in Retinal Detachment Surgery N/A
Completed NCT01445028 - Isotretinoin for Proliferative Vitreoretinopathy Phase 4
Recruiting NCT00370760 - Oral Colchicine Combined With Intravitreal Infusion of Dexamethasone, LMW Heparin and 5-FU for Management of Proliferative Vitreoretinopathy (PVR) Phase 3
Completed NCT00000140 - The Silicone Study Phase 3
Completed NCT06166914 - Efficacy of 5-fluorouracil and Low Molecular Weight Heparin in High-risk Pediatric Retinal Detachment N/A
Recruiting NCT04580147 - Intravitreal Aflibercept for the Prevention of Proliferative Vitreoretinopathy Following Retinal Detachment Repair Phase 2
Completed NCT04891991 - Intravitreal Infliximab for Proliferative Vitreoretinopathy Phase 2
Completed NCT01255293 - Comparative Study of 1000 Centistoke Versus 5000 Centistoke Silicone Oil for Repair of Complex Retinal Detachments N/A
Completed NCT04136366 - The GUARD Trial - Part 1: A Phase 3 Clinical Trial for Prevention of Proliferative Vitreoretinopathy Phase 3
Recruiting NCT06289205 - "Comparing Methotrexate Usage Techniques to Prevent Proliferative Vitreoretinopaty After Retinal Detachment Vitrectomy" Phase 1/Phase 2
Completed NCT01995045 - Postoperative Pain Control Following Vitreoretinal Surgery Phase 4
Completed NCT04490876 - Outcomes of Extensive Brilliant Blue G-Assisted Internal Limiting Membrane Peeling in Proliferative Vitreoretinopathy
Not yet recruiting NCT06425419 - The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Phase 1
Completed NCT02192970 - Bevacizumab Against Recurrent Retinal Detachment Phase 2
Not yet recruiting NCT04682054 - Molecular Taxonomy of Surgically-harvested Ocular Tissues Defined by Single-cell Transcriptomics N/A
Recruiting NCT05660447 - A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR Phase 2/Phase 3
Not yet recruiting NCT06033703 - Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment Phase 1/Phase 2
Active, not recruiting NCT00371020 - The Effect of 5-FU and LMW Heparin on the Rate of Retinal Redetachment After Silicone Oil Removal in Cases of PVR Phase 3
Completed NCT03727776 - Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR) Early Phase 1